Pacira BioSciences Lauren Riker sells 6,000 shares

Q: How many PCRX shares did Lauren Riker sell, and at what price?

Lauren Riker sold 6,000 common shares at $36.32 per share on October 8, 2026. The option exercise and sale were made under a Rule 10b5-1 trading plan adopted March 12, 2026.

Q: How did Lauren Riker's PCRX stock options vest, and when did they expire?

The option vested as to 25% of the option shares on the first anniversary of the grant date, then as to the remaining shares in successive equal quarterly installments over the subsequent three years. The reported option expiration date was December 7, 2026.

The Senior Vice President, Finance's option vested 25% on the first anniversary of the grant date, then in equal quarterly installments over the subsequent three years.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Pacira BioSciences, Inc. (PCRX) Senior Vice President, Finance Lauren Riker exercised options for 6,000 common shares on October 8, 2026, at an exercise price of $32.35 per share, then sold 6,000 shares at $36.32 per share. The exercise and sale were made under a Rule 10b5-1 trading plan adopted March 12, 2026. The reported option position after the exercise was 0 shares, and the option's expiration date was December 7, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 6,000 shares ($24K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider RIKER LAUREN

Role Senior Vice President, Finance

Sold 6,000 shs ($218K)

Approx. gross sale proceeds $218K

Approx. exercise cost $194K

Approx. pre-tax spread $24K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^{F1, F2}	6,000	$0.00	$0.00
Exercise	Common Stock ^F1	6,000	$32.35	$194K
Sale	Common Stock ^F1	6,000	$36.32	$218K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 62,284.242 shares (Direct)

Footnotes (2)

F1. The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026.
F2. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years.

Key Figures

Options exercised: 6,000 shares Exercise price: $32.35 per share Common shares sold: 6,000 shares +3 more

6 metrics

Options exercised 6,000 shares On October 8, 2026

Exercise price $32.35 per share For the option exercise on October 8, 2026

Common shares sold 6,000 shares On October 8, 2026

Sale price $36.32 per share For the common share sale on October 8, 2026

Option shares following transaction 0 shares Reported following the October 8, 2026 exercise

Option expiration date December 7, 2026 Expiration date reported for the stock option

Key Terms

Rule 10b5-1 trading plan, stock option, quarterly installments

3 terms

Rule 10b5-1 trading plan regulatory

"effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

stock option financial

"The stock option vested and became exercisable"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

quarterly installments financial

"successive equal quarterly installments over the subsequent three years"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PCRX shares did Lauren Riker sell, and at what price?

Lauren Riker sold 6,000 common shares at $36.32 per share on October 8, 2026. The option exercise and sale were made under a Rule 10b5-1 trading plan adopted March 12, 2026.

How did Lauren Riker's PCRX stock options vest, and when did they expire?

The option vested as to 25% of the option shares on the first anniversary of the grant date, then as to the remaining shares in successive equal quarterly installments over the subsequent three years. The reported option expiration date was December 7, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/09/2026 - 07:08 PM Accepted by SEC EDGAR 10/09/2026 - 07:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RIKER LAUREN

(Last)

(First)

(Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE

CALIFORNIA

94005

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Senior Vice President, Finance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/08/2026		M		6,000⁽¹⁾	A	$32.35	68,284.242	D
Common Stock	10/08/2026		S		6,000⁽¹⁾	D	$36.32	62,284.242	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$32.35	10/08/2026		M			6,000⁽¹⁾	⁽²⁾	12/07/2026	Common Stock	6,000⁽¹⁾	$0	0	D

Explanation of Responses:

1. The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026.

2. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	10/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR